Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-3/A

Pre-effective amendment to an S-3 filing

Registration Statements
CORRESP

CORRESP

Other
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.